ArticleTranslational lung cancer research2023

Cost-effectiveness analysis of anlotinib as a third-line or further treatment for advanced non-small cell lung cancer in China.

Qiuyan Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.